The space launch services market is associated with activities carried out by the space launch service providers. It comprises a series of events such as ordering, conversion, construction, stacking and assembly, integration of payload, and launch. The space launch services market came into existence after the launch of Sputnik-1, which is often said to be the start of space age. Thus, soon after this various national programs began to provide these services. Later on, commercial operators and enterprises became the significant clients for government service providers.Also, due to increased use of launching systems for commercial purposes, the opportunity for private launch system manufacturers emerged. The entry of private launch service providers resulted into decrease in the launch per cost and new technologies, marking a new phase for the space launch services market.

Biodegradable plastic is a plastic that decomposes naturally in the environment. This is mainly done by the microorganism present in the environment that breaks down the structure of biodegradable plastic. It is manufactured by micro-organism, renewable raw material, and petrochemicals. Biodegradable plastic is eco-friendly and has no toxicity as it is produced using renewable raw material. This type of plastic is mainly produced using natural plant material, which mainly includes corn oil, orange peels, starch, and plants. The report on biodegradable plastic exclusively focuses on current market trends and future growth opportunities of various types of biodegradable plastic such as polylactic Acid (PLA), Polybutylene adipate terephthalate ((PBAT), Polybutylene Succinate (PBS), Polyhydroxyalkanoates (PHA), Starch Blends, and others. On the basis of application, the market is divided into packaging, agriculture, textile, consumer durable, and others. Based on region, it is studied across North America, Europe, Asia-Pacific, and LAMEA.

DNA damage leads to the incorporation and accumulation of aberrations and defects in the genome, which results in potential mutations. The occurrence of mutations in genes having vital proteins or enzymes leads to the development of cancer. However, the biological system is equipped with an effective repair mechanism capable of repairing the damaged DNA sequences in the cells. DNA damage response (DDR) drugs are used as a therapeutic strategy for augmenting the innate DNA repair mechanism, thereby aiding advanced cancer treatments. The development of DDR drugs potentially harnesses proteins involved in the DDR pathway such as Poly (ADP-ribose) polymerase (PARP), WEE1, Aurora B, ATM kinase, and ATR kinase.

DNA methylation is a heritable epigenetic marker which involves the covalent transfer of a methyl group to the C-5 position of the cytosine ring of DNA by enzymes known as DNA methyltransferases (DNMTs). In humans, DNA methylation occurs primarily at cytosines in any context of the genome. More than 98% of DNA methylation occurs in a CpG dinucleotide context in somatic cells. The current study aims to assess the global DNA methylation market by focusing on evaluating products catering to the aforementioned definition. The current scenario of DNA methylation detection and diagnosis is mainly dominated by several diagnostic majors, such as Illumina, Inc., Thermo Fisher Scientific Inc., Merck Group, and QIAGEN N.V., which offer a wide variety of products ranging from molecular-genetic tests to sequencing instruments for the confirmatory detection and diagnosis of DNA methylation. These products are generally based on technologies, such as polymerase chain reaction (PCR), microarrays, and sequencing, including both traditional and next-generation sequencing. The underlying utility of diagnostic testing for DNA methylation is based on the identification of clinically actionable genetic function, which provide crucial information on diagnosis, prognosis, and theranostics of genetic disorders and thereby facilitates clinical work-up, treatment management, and therapeutic selection.

Drug screening is used to identify prescription drugs and illicit drugs in urine, plasma, and other biological samples. Urine testing is the most commonly used sample type for drug screening. The report provides market dynamics and trends related to the global drug screening laboratory services market. In addition, it presents estimations and forecast of the drug screening services market majorly performed for various workplaces. The study estimates revenue generated from the services offered. The valuations comprise revenue generated from drug laboratory services. However, the report excludes revenues generated by counseling fees of doctors or healthcare providers who suggest various types of drug screening tests.

The global cell & gene therapy market is one of the fastest-growing segments of the global regenerative medicine market. The market is growing at a healthy rate and this trend is expected to continue during the forecast period. This surge can be attributable to the growing prevalence of various chronic diseases like cancer, cartilage related problems, wounds, diabetic foot ulcer, genetic diseases, and other rare diseases across the globe. For instance, the prevalence of cancer and diabetes is increasing among the global population, and the medical solutions through conventional treatment methods are limited. There is a large unmet need in the treatments available today, and this need is fulfilled by cell & gene therapies. The market is witnessing steady growth due to the increased availability of funding from various public and private institutes. In addition, there is increased support from the regulatory bodies for product approvals and providing fast-track designations to the products, which encourages vendors to manufacture the products at a faster rate. In addition, the government in various major nations is creating awareness about the cell & gene therapy among the population and bringing various strategies to facilitate affordability and payments for these treatments.